{"organizations": ["Novartis", "GSK", "Novartis AG"], "uuid": "5f9fea3555afce727b4e5d5bc01c8c41241c9e58", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "us.rd.yahoo.com", "main_image": "", "site_section": "http://finance.yahoo.com/rss/headline?s=NVS", "section_title": "Yahoo! Finance: NVS News", "url": "http://us.rd.yahoo.com/finance/external/noodlsaunz/rss/SIG=1253pgjat/*http://www.noodls.com/view/03ADDDD0995582A5C007B27046811FD6529DB959", "country": "US", "title": "Novartis acquires all remaining rights to GSK's Ofatumumab to develop treatments for MS and other autoimmune indications", "performance_score": 0, "site": "yahoo.com", "participants_count": 0, "title_full": "Novartis acquires all remaining rights to GSK's Ofatumumab to develop treatments for MS and other autoimmune indications", "spam_score": 0.0, "site_type": "news", "published": "2015-08-21T08:56:00.000+03:00", "replies_count": 0, "uuid": "5f9fea3555afce727b4e5d5bc01c8c41241c9e58"}, "author": "", "url": "http://us.rd.yahoo.com/finance/external/noodlsaunz/rss/SIG=1253pgjat/*http://www.noodls.com/view/03ADDDD0995582A5C007B27046811FD6529DB959", "ord_in_thread": 0, "title": "Novartis acquires all remaining rights to GSK's Ofatumumab to develop treatments for MS and other autoimmune indications", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "Novartis AG 21/08/2015 | Press release Novartis acquires all remaining rights to GSK's Ofatumumab to develop treatments for MS and other autoimmune indications \ndistributed by noodls on 21/08/2015 05:51", "external_links": [], "published": "2015-08-21T08:56:00.000+03:00", "crawled": "2015-08-21T11:30:11.319+03:00", "highlightTitle": ""}